← FDA DRUG APPROVALS

FDA ANDA · ANDA208438

ARIPIPRAZOLE

Sponsor: PHARMTAK INC

APPLICATION
ANDA208438
TYPE
ANDA
ROUTE
ORAL
DOSAGE FORM
TABLET, ORALLY DISINTEGRATING
MARKETING STATUS
None (Tentative Approval)

Products

ARIPIPRAZOLENone (Tentative Approval)
ARIPIPRAZOLE 10MG · TABLET, ORALLY DISINTEGRATING · ORAL
ARIPIPRAZOLENone (Tentative Approval)
ARIPIPRAZOLE 15MG · TABLET, ORALLY DISINTEGRATING · ORAL

Approval history

2018-12-26UNKNOWN · Original · standardTA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →